Crinetics Pharmaceuticals Inc

Research Crinetics Pharmaceuticals Inc (CRNX) on Bullrun: market cap USD 3.89B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCRNX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 3.89B
• Financial periodFY2025
• RevenueUSD 7.70M
• Revenue growth640.7%
• Net income-USD 465.30M
• Free cash flow-USD 383.68M
• Gross margin86.0%

Valuation Snapshot

latest market cap is USD 3.89B.

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors.

Frequently asked questions

What is Crinetics Pharmaceuticals Inc's market cap?

Crinetics Pharmaceuticals Inc's market capitalization is USD 3.89B.

What does Crinetics Pharmaceuticals Inc do?

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.